Clinical Ink, a global clinical trial technology company, today announced its acquisition by GI Partners, a leading private equity investment firm. Existing investor NovaQuest will continue as a minority investor in the company and Clinical Ink’s management team also invested significantly in the transaction. Clinical Ink’s service-first methodology and dedication to supporting a wide range of deployment options enable confident decisions, faster, and have driven meaningful industry adoption. Over the past three years, the company has tripled its bookings, quadrupled its revenues, and backlog has grown by 500%.
Read the full article: Clinical Ink Announces Its Acquisition by GI Partners //
Source: https://www.businesswire.com/news/home/20200804005150/en/Clinical-Ink-Announces-Acquisition-GI-Partners